INDIRECT COMPARISON OF PEMBROLIZUMAB TO VEMURAFENIB AND DABRAFENIB MONOTHERAPY FOR FIRST-LINE TREATMENT OF ADVANCED MELANOMA IN BRAF MUTATION POSITIVE IPILIMUMAB NAIVE PATIENTS

被引：1
|
作者：
Jansen, J. P. [1 ]
Stevinson, K. [2 ]
Wang, J. [3 ]
机构：
[1] Precis Hlth Econ, San Francisco, CA USA
[2] Merck & Co Inc, Lebanon, NJ USA
[3] Merck & Co Inc, North Wales, PA USA
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 03期
关键词：
D O I：
10.1016/j.jval.2016.03.1650
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN28
引用
收藏
页码：A138 / A138
页数：1
相关论文
共 50 条
  • [1] First-line pembrolizumab versus dabrafenib/trametinib treatment for BRAF V600-mutant advanced melanoma
    Kim, Chang Gon
    Kim, Miso
    Hwang, Jieon
    Kim, Seung Tae
    Jung, Minkyu
    Kim, Kyoo Hyun
    Kim, Kyung Hwan
    Chang, Jee Suk
    Koom, Woong Sub
    Roh, Mi Ryung
    Chung, Kee Yang
    Kim, Tae Min
    Kim, Sang Kyum
    Lee, Jeeyun
    Shin, Sang Joon
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (05) : 989 - 996
  • [2] Indirect comparison of pembrolizumab monotherapy versus nivolumab plus ipilimumab in first-line metastatic lung cancer
    Halmos, Balazs
    Burke, Thomas
    Kalyvas, Chrysostomos
    Insinga, Ralph
    Vandormael, Kristel
    Frederickson, Andrew
    Piperdi, Bilal
    IMMUNOTHERAPY, 2022, 14 (05) : 295 - 307
  • [3] COST-EFFECTIVENESS EVALUATION OF SEQUENTIAL TREATMENT STATEGIES FOR TREATMENT NAIVE PATIENTS WITH BRAF MUTANT METASTATIC MELANOMA IN UK: NIVOLUMAB PLUS IPILIMUMAB FIRST-LINE VERSUS DABRAFENIB PLUS TRAMETINIB FIRST-LINE
    Tokarz, A.
    Cai, R.
    Baginska-Dudek, B.
    Yates, G.
    Srinivasan, S.
    Okorogheye, G.
    Palaia, J.
    McDonald, L.
    VALUE IN HEALTH, 2024, 27 (12) : S106 - S106
  • [4] Cost-Effectiveness Analysis of Dabrafenib Plus Trametinib and Vemurafenib as First-Line Treatment in Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma in China
    Gao, Tianfu
    Liu, Jia
    Wu, Jing
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2021, 18 (12)
  • [5] Cost Effectiveness of Dabrafenib as a First-Line Treatment in Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma in Canada
    Delea, Thomas E.
    Amdahl, Jordan
    Wang, Alice
    Amonkar, Mayur M.
    Thabane, Marroon
    PHARMACOECONOMICS, 2015, 33 (04) : 367 - 380
  • [6] Cost Effectiveness of Dabrafenib as a First-Line Treatment in Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma in Canada
    Thomas E. Delea
    Jordan Amdahl
    Alice Wang
    Mayur M. Amonkar
    Marroon Thabane
    PharmacoEconomics, 2015, 33 : 367 - 380
  • [7] COST-EFFECTIVENESS OF VEMURAFENIB AS A FIRST-LINE TREATMENT IN PATIENTS WITH BRAF V600 MUTATION-POSITIVE UNRESECTABLE OR METASTATIC MELANOMA IN SPAIN
    Rubio-Terres, C.
    Orofino, J.
    Armas, J.
    Parra, J.
    Rubio-Rodriguez, D.
    Grau, S.
    VALUE IN HEALTH, 2015, 18 (07) : A453 - A453
  • [8] Comparative safety of BRAF and MEK inhibitors (vemurafenib, dabrafenib and trametinib) in first-line therapy for BRAF-mutated metastatic melanoma
    Cebollero, Ana
    Puertolas, Teresa
    Pajares, Isabel
    Calera, Lourdes
    Anton, Antonio
    MOLECULAR AND CLINICAL ONCOLOGY, 2016, 5 (04) : 458 - 462
  • [9] Indirect Treatment Comparison of Talimogene Laherparepvec Compared with Ipilimumab and Vemurafenib for the Treatment of Patients with Metastatic Melanoma
    Quinn, Casey
    Ma, Qiufei
    Kudlac, Amber
    Palmer, Stephen
    Barber, Beth
    Zhao, Zhongyun
    ADVANCES IN THERAPY, 2016, 33 (04) : 643 - 657
  • [10] Indirect Treatment Comparison of Talimogene Laherparepvec Compared with Ipilimumab and Vemurafenib for the Treatment of Patients with Metastatic Melanoma
    Casey Quinn
    Qiufei Ma
    Amber Kudlac
    Stephen Palmer
    Beth Barber
    Zhongyun Zhao
    Advances in Therapy, 2016, 33 : 643 - 657
12345